News Sanofi/Lexicon's sotagliflozin filed in US and EU for type 1... Regulators in the US and Europe are to review Sanofi/Lexicon’s sotagliflozin in type 1 diabetes, a potential blockbuster pill.
News Ablynx drug fails in mid-stage lupus trial Ablynx’s vobarilizumab has failed in a mid-stage trial in lupus, with the biotech’s multi-billion buyout from Sanofi just around the corner.
Partner Content Partner Content Sanofi Joins the Speaker Line-up for SMi's Launch, Injectabl... Injectable Drug Delivery
News Sanofi passes on Alnylam's breakthrough therapy Alnylam is to forge ahead with a rare disease therapy on its own after Sanofi decided to opt out of a co-development and co-marketing deal.
News Double blow to Amgen with Sanofi's Praluent data and price c... Sanofi and Regeneron have scored a major victory in their fight with Amgen in the market for cardiovascular drugs, after releasing data showing their Praluent injection reduces risk of card
News Sanofi in talks with Evotec to out-licence antibiotic resear... Evotec to collaborate with academia, pharma and biotech on new antimicrobials
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.